ReviewFrontiers in medicine2023
The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis.
Review in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Integration of GWAS, QTLs and keratinocyte functional assays reveals molecular mechanisms of atopic dermatitis.Nature communications · 2025Pooled it
- Sex- and Gender-Related Differences in Pruritus in Dermatological Diseases: Insights into Inflammatory, Autoimmune, and Connective Tissue Disorders.Life (Basel, Switzerland) · 2026Review
- Single-cell transcriptome reveals keratinocyte subclusters contributing to altered differentiation and inflammatory responses in atopic dermatitis.Nature communications · 2026Article
- Transcriptomic Effects of Oclacitinib and Prednisolone in an Acute IgE-Mediated Experimental Model of Canine Atopic Dermatitis.Veterinary sciences · 2026Article
- Oral Administration ofAnimals : an open access journal from MDPI · 2026Article
- Examining the immunomodulatory role of nanoparticles on mast cell activation.Scientific reports · 2026Article
- Serum Cytokine Profiles and Their Association with Clinical Severity in Dogs with Atopic Dermatitis.Animals : an open access journal from MDPI · 2026Article
- IL-13 and skin fibrosis in inflammatory skin diseases.Frontiers in immunology · 2026Review
- Inflammatory and fibrotic biomarkers in patients with atopic dermatitis treated with cendakimab.The journal of allergy and clinical immunology. Global · 2026Article
- Immunological and molecular biomarkers in skin allergy therapy: monitoring inflammation, barrier function, and treatment response.Postepy dermatologii i alergologii · 2026Review
- Association betweenFrontiers in medicine · 2026Article
- Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study.Dermatology and therapy · 2025Article
- Massively parallel analysis of genotype-dependent enhancer activity among atopic dermatitis genetic risk variants.The Journal of allergy and clinical immunology · 2025Article
- Stress mediates the association between atopic dermatitis and sleep duration in Korean adults.Scientific reports · 2025Article
- Review
- Comparative Efficacy and Safety of Tralokinumab and Dupilumab in Moderate-to-Severe Atopic Dermatitis: A Narrative Review.Journal of clinical medicine · 2025Review
- Population Pharmacokinetic-Pharmacodynamic (popPK/PD) Relationship of Orismilast, A Potent and Selective PDE4B/D Inhibitor, in Atopic Dermatitis.Dermatology and therapy · 2025Article
- Exploring the Link Between Atopic Dermatitis and Eosinophilic Esophagitis.The Journal of clinical and aesthetic dermatology · 2025Review
- An Overview of Atopic Dermatitis Disease Burden, Pathogenesis, and the Current Treatment Landscape: Recommendations for Appropriate Utilization of Systemic Therapies.The Journal of clinical and aesthetic dermatology · 2025Review
- Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment.American journal of clinical dermatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent evidence suggests that interleukin (IL)-13 is a crucial cytokine involved in the pathogenesis of atopic dermatitis (AD). It is a central driver of type-2 T-helper inflammation and is overexpressed in lesional skin of AD patients. Upon release in peripheral skin, IL-13 activates its receptors, recruits inflammatory cells, and modifies the skin microbiome. IL-13 also reduces the expression of epidermal barrier proteins and activates sensory nerve mediating the itch transmission signal. Novel therapeutics that target IL-13 seem to be efficacious and safe for the treatment of patients with moderate-to-severe AD. The aim of our manuscript is to review the role that IL-13 plays in AD immunopathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.